Search results
Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU
Zacks via Yahoo Finance· 5 months agoRoche RHHBY announced that the European Commission has granted marketing authorization to...
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
Zacks via Yahoo Finance· 1 year agoRoche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating...
Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion
Zacks via Yahoo Finance· 7 months agoRoche RHHBY announced that the European Medicines Agency’s Committee for Medicinal Products for...
Roche (RHHBY) Announces Data on Tecentriq Combo for HCC
Zacks via Yahoo Finance· 1 year agoRoche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of...
Advanced Lung Cancer and Immunotherapy
Verywell Health via Yahoo News· 9 months agoImmunotherapy is a newer class of treatment for lung and other cancers. It primes the body’s natural immune system to fight back against cancer....
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
Clinical Trials Arena via Yahoo Finance· 4 weeks agoUS-based gene therapy company Genprex has enrolled and dosed the first subject in a Phase I/II trial...
FDA approves Amgen drug for tough-to-treat form of lung cancer
BioPharma Dive via Yahoo Finance· 3 weeks agoImdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following...
Brazilian soccer legend Pelé died of colon cancer. Here are the cutting-edge clinical trials trying...
Business Insider via Yahoo News· 1 year agoPelé died of colon cancer, one of the most common types.Clive Mason/Getty The Brazilian soccer...
First-Line Treatment for Lung Cancer
Verywell Health via Yahoo News· 2 years agoWhen you are diagnosed with lung cancer, the preferred initial treatment is called the first-line treatment. It may also be referred to as induction...
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
Zacks via Yahoo Finance· 10 months agoExelixis, Inc. EXEL and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of...